EZH2与癌症

EZH2 and Cancer

果蝇zeste基因增强子的人类同源物2(EZH2)编码组蛋白甲基转移酶EZH2,与其他关键蛋白共同组成多梳抑制复合物PRC2,通过催化组蛋白H3第27位赖氨酸的三甲基化发挥转录抑制作用。研究发现,在多种恶性肿瘤细胞中存在EZH2的突变及异常表达,这些异常导致了某些抑癌基因的沉默,与癌症的发生、发展、转移、侵袭及预后不良有重要关系。目前,EZH2作为癌症治疗的靶标成为了研究热点,其抑制剂也作为新型癌症靶向药物,投入临床试验及应用。该文对EZH2的肿瘤生物学效应及其在癌症治疗等领域的应用进行综述,以期更加清晰地展示EZH2在肿瘤学领域的研究价值。

Enhancer of zeste homolog 2(EZH2)encodes histone methyltransferase EZH2,which forms the polycomb repressive complex 2(PRC2)with other key proteins,repressing the transcription process through catalyzing trimethylation of the 27 th lysine of histone H3.Researchers have found that there are mutations and abnormal expressions of EZH2 in a variety of malignant tumor cells.These abnormalities lead to the silencing of certain tumor suppressor genes,which are significantly correlated with the occurrence,development,metastasis,invasion and poor prognosis of cancer.Nowadays,EZH2 has become a hot research topic as a target for cancer treatment,the inhibitors of which have also been put into clinical trials and applications as new cancer targeted drugs.This article reviews the biological effects of EZH2 and its application in cancer treatment,so as to demonstrate the research value of EZH2 in the field of oncology.